Source: Proactive Investors
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medexus Pharmaceuticals (MDP) has appointed Marcel Konrad as Chief Financial Officer
  • Mr. Konrad brings over 20 years of experience in accounting, finance and business across various global markets
  • Mr. Konrad holds an International MBA from the University of San Diego
  • Mr. Konrad is an active US Certified Public Accountant and has completed the Finance Leadership Program at the Harvard Business School
  • Medexus Pharmaceuticals is a leader in innovative rare disease treatment solutions
  • Medexus Pharmaceuticals Inc. (MDP) opened trading at C$7.70 per share

Medexus Pharmaceuticals (MDP) has appointed Marcel Konrad as Chief Financial Officer, effective immediately.

Mr. Konrad succeeds Roland Boivin, who is stepping down after nearly a decade in the role. Mr. Boivin has agreed to stay in an advisory capacity in order to help ensure an orderly transition of responsibilities to Mr. Konrad over the next few months.

“I want to take this opportunity on behalf of all of us at Medexus to thank Roland for all of his efforts and dedicated service and to wish him the very best in his future endeavours,” said Ken d’Entremont, the Company’s Chief Executive Officer.

“I am grateful for the opportunity to have worked with the entire Medexus team and to have played a key role in transitioning the company from a small Canadian-only player into a North-American commercial leader in innovative orphan drug and rare disease products,” said Roland Boivin. “I’m confident that Medexus is positioned to continue to prosper and I look forward to working with Mr. Konrad, Ken and the executive team to ensure a smooth transition.”

Mr. Konrad brings over 20 years of experience in accounting, finance and business across various global markets, including the United States. Mr. Konrad joins the company from CareDx, Inc., where he has served as Senior Vice President Finance & Accounting and Vice President, Corporate Controller since 2018, including a stint as acting Chief Financial Officer in early 2021. While at CareDx, Inc., Mr. Konrad was tasked with scaling multinational accounting, finance and business operations including streamlining processes and systems while navigating the integration of various financings and cross-border acquisitions.

Prior to joining CareDx, Inc., Mr. Konrad worked in similar roles at Santen Inc., a US subsidiary of a publicly listed Japanese pharmaceutical company with global operations, and held various roles at Novartis Pharmaceuticals, both in the US and Switzerland.

Mr. Konrad holds an International MBA from the University of San Diego and graduated Business Administration from HEC Lausanne, University of Lausanne, Switzerland.

Mr. Konrad is an active US Certified Public Accountant and during his tenure at Novartis has completed the Finance Leadership Program at the Harvard Business School.

“Marcel brings to Medexus a combination of financial acumen, strategic and industry expertise and global operational leadership experience that will be invaluable to the Company. We very much look forward to Marcel beginning his Medexus journey,” Mr. d’Entremont said.

Medexus Pharmaceuticals is a leader in innovative rare disease treatment solutions with a strong North American commercial platform. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy.

Medexus Pharmaceuticals Inc. (MDP) opened trading at C$7.70 per share.

More From The Market Herald

" Hemostemix (TSXV:HEM) announces non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 15 million units.
WELL Health - Chairman & CEO Hamed Shahbazi

" WELL Health (TSX:WELL) closes $34.5M public offering

WELL Health Technologies Corp. (WELL) has completed a bought deal public offering for proceeds of $34.5 million.

" Simply Better Brands (TSXV:SBBC) enters the weight loss category

Simply Better Brands (SBBC) has launched its entry into the weight loss category with a PureKana Keto Gummy.

" Cardiol Therapeutics (TSX:CRDL) appoints new directors

Cardiol Therapeutics (CRDL) has appointed Teri Loxam and Chris Waddick to its Board of Directors, effective immediately.